Introduction
The development of T cells expressing T cell receptors (TCRs) bearing a precise specificity for peptides embedded in self-HLA (MHC) molecules occurs in the thymus. At this site, T cell interactions with thymic epithelial cells (TECs) establish an individualized TCR repertoire. The developmental progression of T cells occurs in several stages and involves 2 distinct epithelial cell (EC) subsets, cortical and medullary TECs (1, 2). Designated by their distribution within the thymus, these subsets are functionally distinct despite developing from a common precursor cell (3) . Cortical TECs (cTECs) support early T cell development. They release chemokines such as Ccl19, Ccl21, and Ccl25 to direct early thymocyte precursor entry at a cortical-medullary interface (4) . cTECs also secrete IL-7, and in conjunction with the chemokines, combinatorially provide proliferation, differentiation, and directional information to the immature double-negative (DN) CD4 -CD8thymocyte subset (4) . This is further determined by the expression on cTECs of delta ligand-like 4 (DDL4), which binds to Notch on immature thymocytes and leads to expression of the Notch-acti-vated transcription factor RBPJκ. The various cTEC-dependent signals promote chromosome rearrangements at the TCRβ locus in the DN thymocytes. Successful expression of a TCRβ protein signals an expansion and differentiation phase of the DN cells into the double-positive (DP) CD4 + CD8 + subset. During this transition, the TCRα locus is rearranged, with a productively produced TCRα protein pairing with the TCRβ subunit. A byproduct of this rearrangement event is the TCR excision circle (TREC), which is the newborn screening analyte used to identify patients with SCID (5) .
The survival of an αβ TCR-expressing DP thymocyte is enabled after favorable "weak" TCR interactions with self-peptides bound to MHC molecules presented by the cTECs (positive selection). The positively selected thymocytes are directed into the CD4 + CD8and CD4 -CD8 + single-positive (SP) subsets that enter the medullary regions. The expansion and function of medullary TECs (mTECs) relies on their crosstalk with SP thymocytes, with CD40L, RANKL, and EGF engaging CD40, RANK, and EGFR, respectively, on the TECs (6, 7) . The mTECs present many tissue-restricted antigens on HLA molecules, a process that requires the transcriptional regulator termed AIRE, along with a second transcription factor, Fezf2 (8, 9) . mTECs purge T cells with high-affinity, self-reactive TCR specificities (negative selection). An added function of mTECs is to support the selection of Tregs (10) . The selected Tregs exit into the peripheral lymphoid organs, where they prevent the promiscuous activation of any remaining autoreactive T cells (11) . The gauntlet of cTEC-and mTECmediated T cell selection processes, aided by DCs, results in pro-We report on 2 patients with compound heterozygous mutations in forkhead box N1 (FOXN1), a transcription factor essential for thymic epithelial cell (TEC) differentiation. TECs are critical for T cell development. Both patients had a presentation consistent with T -/lo B + NK + SCID, with normal hair and nails, distinct from the classic nude/SCID phenotype in individuals with autosomal-recessive FOXN1 mutations. To understand the basis of this phenotype and the effects of the mutations on FOXN1, we generated mice using CRISPR-Cas9 technology to genocopy mutations in 1 of the patients. The mice with the Foxn1 compound heterozygous mutations had thymic hypoplasia, causing a T -B + NK + SCID phenotype, whereas the hair and nails of these mice were normal. Characterization of the functional changes due to the Foxn1 mutations revealed a 5-amino acid segment at the end of the DNA-binding domain essential for the development of TECs but not keratinocytes. The transcriptional activity of this Foxn1 mutant was partly retained, indicating a region that specifies TEC functions. Analysis of an additional 9 FOXN1 mutations identified in multiple unrelated patients revealed distinct functional consequences contingent on the impact of the mutation on the DNA-binding and transactivation domains of FOXN1.
FOXN1 compound heterozygous mutations cause selective thymic hypoplasia in humans with alopecia universalis and nail plate dystrophy (23, 25, 28) . Thymic hypoplasia/aplasia arising from defects with stromal cell populations such as TECs can also occur in individuals with mutations in CHD7, PAX1, TBX1, and TBX2, and in those with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome) (29) (30) (31) (32) (33) (34) (35) . However, only the autosomal-recessive mutations described for FOXN1 lead to the additional developmental problems of the hair shaft and nail plate.
We report here on the identification of mutations in FOXN1 in 2 patients with a T -/lo B + NK + SCID without evidence of alopecia or nail dystrophy. We used CRISPR-Cas9 technology to develop Foxn1 compound heterozygous mice that genocopied selected human FOXN1 mutations. A comparison of the various mice harboring homozygous and compound heterozygous Foxn1 mutations revealed differential functions of this transcription factor in TECs versus keratinocytes. Phenotype analyses and functional assays revealed an important 5-amino acid sequence in Foxn1 that differentiates its role in TECs versus keratinocytes. A comparative analysis of 12 distinct FOXN1 mutations, identified in patient 1 (Pt. 1) and patient 2 (Pt. 2) as well as in several unrelated patients with heterozygous mutations, revealed varying transcriptional activities depending on the location and type of mutation. These findings provide structure-function insights into this key transcription factor.
Results
Compound heterozygous mutations in FOXN1 identified in 2 unrelated patients with a SCID phenotype without alopecia. Pt. 1 was a female born at full term to nonconsanguineous parents and was identified as having SCID following newborn screening that revealed undetectable TRECs. The subsequent clinical work-up was consistent with a typical T -B + NK + SCID phenotype, using the normal age-matched reference range (Table 1) (36, 37) . Exome sequencing revealed 2 mutations in the FOXN1 gene, a duplication grammed cell death for the vast majority of thymocytes. What emerges from the thymus is a population of mature T cells with a precise TCR specificity unique to a given individual.
The development and differentiation of TECs into the cortical and medullary subsets are established by the transcription factor forkhead box N1 (FOXN1) (1, 12) . FOXN1 belongs to a large family of proteins defined by a conserved, 100-amino-acid-long DNA-binding domain called the forkhead or winged helix. Forkhead family members are present in species from yeast to humans, but not in plants (13, 14) . FOXN1 arose via duplication of FOXN4, an ancestral homolog that first appeared in those early chordates with evidence of a thymus (1, 15, 16) . Comprising 3 α helices, 3 β sheets, and 2 loops designated as the wings, the third α helix of FOXN1 contacts the major groove of DNA (17) . The second winged segment provides additional binding specificity within the minor groove of DNA. Foxn1 interacts with DNA sequences containing a GAa/cGC consensus and transcriptionally activates nearly 500 genes including keratins, cytokeratins, proteasome components, and cell-surface proteins (2) . A transactivation domain near the COOH-terminal half of the protein is also required for Foxn1 functions (18) .
The importance of FOXN1 in TEC and keratinocyte development was first uncovered in a spontaneously arising nude phenotype in mice (nu/nu), which was later shown to be caused by autosomal-recessive mutations in this gene (12, 19) . The loss of Foxn1 protein expression results in a TEC deficiency in combination with structural defects of the hair shaft and nail beds (12, 20, 21) . This is the basis of the T -B + NK + nude/SCID phenotype. Since the original description of nude mice in 1966 and later, of nude rats, 3 distinct autosomal-recessive mutations in human FOXN1 have been reported in approximately 10 patients, all of whom presented with similar nude/SCID phenotypes (22) (23) (24) (25) (26) . This phenotype is also described in Birman cats (27) . The classic clinical presentations for humans with autosomal-recessive FOXN1 mutations include a T -B + NK + SCID phenotype due to thymic aplasia in conjunction 
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The proliferation assays were conducted in 3 different laboratories; the initial mitogen proliferation used anti-CD3, anti-CD28, and anti-IL-2 stimulation, whereas the subsequent 2 assays were performed using phytohemagglutinin stimulation at 2 separate laboratories. ALC, absolute lymphocyte count; PHA, phytohemagglutinin. Gln489Argfs on the second allele that resulted in a frameshift mutation in the protein (Figure 1 , B, C, and E). The 1288 variant is a polymorphism found in 4% of the general population (dbSNP: rs61749867), but the impact of this variant on FOXN1 has not been established. Analysis of the parents indicated that the c.C1288T variant was inherited from the mother, whereas the c.1465delC variant was de novo. The FOXN1 mutations described for both Pt. 1 and Pt. 2 are distinct from the classic autosomal-recessive mutations originally identified in FOXN1 ( Figure 1C ) (22) (23) (24) (25) (26) . To date, previously identified mutations on other genes associated with SCID or cellular immunodeficiency phenotypes were not found in Pt. 1 or Pt. 2 ( Table 2) .
Mice harboring compound heterozygous mutations in Foxn1 have thymic hypoplasia with normal fur and nail beds. To confirm that the FOXN1 mutations in Pt. 1 were causal to the SCID phenotype, we used a CRISPR-Cas9 strategy to create analogous mutations in C57Bl/6 mice. Individual guide RNAs were designed with Cas9 cleavage sites near the equivalent positions in the murine locus of ACCC at position c.933 (c.933_936dup), and a 15-nt deletion (c.1089_1103del) ( Table 2 ). Analysis of the parental data indicated that the 933 mutation was inherited from the mother, whereas the 1089 mutation was passed down from the father. Both parents were healthy and had no evidence of hair loss or nail changes ( Figure 1 , A, C, and D; Family 1). The c.933 duplication was identified as a presumed pathogenic variant that was predicted to result in a premature stop codon following a new coding sequence of approximately 169 amino acids extending from the middle of the DNA-binding domain (p.Thr313fs*169). The second allele in Pt. 1 contained a 15-nt deletion near the end of the DNA-binding domain. This resulted in a single amino acid conversion (Trp to Cys) followed by a 5-amino acid deletion (p.Trp363_Pro367delin-sCys) ( Figure 1 , A and C). The deletion did not change the reading frame. The clinical course for Pt. 1 was characterized by rhino/ enteroviral infection at 2 months of age, norovirus enteritis and failure to thrive starting at 5 months, and parainfluenza virus type 3 (PIV3) at 9 months ( Table 2 ). Although this infant was a candidate for allogeneic thymic tissue transplantation, the recurring viral infections resulted in her death before 1 year of age. This was a consequence of respiratory failure with disseminated PIV3, with identification of the virus also in liver biopsies.
Pt. 2, born to nonconsanguineous parents, also had undetectable TRECs following newborn screening. Serial immune testing was consistent with a T -/lo B + NK + leaky SCID phenotype with mental material available online with this article; https://doi. org/10.1172/JCI127565DS1). DNA sequencing of these runts revealed deletions within the DNA-binding domain on both Foxn1 alleles. In contrast, the 1089 founders appeared visually indistinguishable from normal mice ( Figure 2B and Supplemental Figure  1A ). Founders with the correct nucleotide duplication (933 nt) or deletion (1089 nt) in Foxn1 were bred with WT mice, followed by intercrossing of the mice to establish the appropriate homozygous and compound heterozygous lines. F2-generation mice homozygous for the 933 mutation (Foxn1 933/933 ) were small and hairless and had diminished nail lengths and shortened whiskers compared with littermate controls ( Figure 2B and Supplemental Figure 1B ). These phenotypes matched that of the classic nu/nu mouse (12) . In contrast, the physical appearance of the Foxn1 1089/1089 and Foxn1 933/1089 mice matched that of their littermate controls ( Figure 2B ). The Foxn1 933/933 mice had thymic aplasia, with a 35-to 50-fold reduction in thymus weights compared with littermate control thymus weights ( Figure  2 , C and D). The Foxn1 1089/1089 and Foxn1 933/1089 compound hetero-for Pt. 1, at positions 933 and 1089 ( Figure 2A ). Silent mutations were included to create new DNA restriction sites for genotyping purposes. The more difficult design was for position 933 (Pt. 1). At this location, the 4-nt duplication (ACCC) in human FOXN1 creates a frameshift that begins mid-way through the DNA-binding domain. The corresponding TCCT insertion within the same location in the murine Foxn1 locus creates an immediate stop codon. Consequently, a TCCC insertion was engineered into the murine locus along with several additional nucleotide substitutions within the repair template to better mimic the read-through seen with the patient's allele. The resulting coding sequences for both the human and murine genes following the insertion site were novel, with a new stop codon introduced within exon 6. The corresponding mutations in the human genome led to a longer transcript, again with codons unrelated to WT FOXN1.
The phenotypes of the founder pups derived from the CRISPR-Cas9 genome editing of the Foxn1 933-nt position were distinct from those targeted at position 1089. Many of the 933 pups had a nude, runted phenotype (Supplemental Figure 1A ; supple- how the diverse FOXN1 mutations affect thymopoiesis, we compared the developmental progression of thymocytes in the different mouse lines ( Figure 3A ). We monitored the various stages by comparing the cell-surface expression of the CD4, CD8, TCRβ, CD25, CD44, CD45, and CD69 by flow cytometry. As shown in the littermate controls (Foxn1 WT/WT ), thymopoiesis was characterized by a subset of immature CD4 -CD8cells (DN, 4%) that developed into a CD4 + CD8 + cell population (DP, 80%-87%), of which a small number were positively selected into the CD4 + CD8 -(CD4 SP, 3%-8%) and CD4 -CD8 + lineages (CD8 SP, 2%-5%) ( Figure  3A ). With the exception of some DN and CD8 lo cells, the DP and SP cell populations were virtually nonexistent in the Foxn1 933/933 mouse line ( Figure 3A) . The DN and CD8 lo cell populations lacked CD45 + cell-surface expression, indicating that they were not thy-zygous mice had pronounced thymic hypoplasia, with a 10-and 17-fold reduction in thymus weights, respectively ( Figure 2 , C and D). This was confirmed when we compared the total thymic cellularity of 6 to 22 mice per group ( Figure 2D ). Sex was not a determinant for the hypoplasia, as males and females were equally affected (Supplemental Figure 2A) . A comparison of the various heterozygous mice derived from the intercrosses (Foxn1 WT/1089 and Foxn1 WT/933 ) revealed no impact of a single-allele mutation on thymic cellularity, T cell development, and/or peripheral lymphocytes compared with littermate controls (Supplemental Figure 2 , B-E). These findings firmly establish that the clinical phenotypes of Pt. 1 resulted from compound heterozygous mutations in FOXN1. Thymopoiesis is severely attenuated in mouse lines with compound heterozygous mutations in Foxn1 that genocopy Pt. 1. To understand mocytes ( Figure 3A , data not shown). This finding concurs with the cystic thymic rudiment described for the nu/nu mice, which was devoid of thymocytes (38) . The Foxn1 1089/1089 homozygous knockin mice had an increased percentage of DP thymocytes (90%-95%) with severely reduced SP subsets compared with controls. Such results suggest that homozygous mutations at the 1089 position of Foxn1 lead to some differentiation of thymocytes to the CD4 + CD8 + stage, at which point there was a developmental block. Thymopoiesis in the Foxn1 933/1089 mice, genocopying Pt. 1, was more severely affected. A significant reduction in the percentage of both DP and SP subsets was obvious, albeit not as extreme as that seen in the Foxn1 933/933 mouse line, a finding consistent with the presence of a small thymic structure ( Figure 2C ). These data confirm that the distinct Foxn1 mutations have dif-ferential consequences for early T cell development and positive selection. We further explored this by characterizing the 4 stages of DN thymocyte progression as DN1-DN4 (DN1: CD44 + CD25 -, DN2: CD44 + CD25 + , DN3: CD44 -CD25 + , DN4: CD44 -CD25 -). We noted similar percentages of each of the DN1-DN4 subsets when we compared Foxn1 1089/1089 thymocytes with those of normal controls ( Figure 3B ). However, the mouse line that genocopied Pt. 1 (Foxn1 933/1089 ) had a selective block at the DN1 stage ( Figure 3B ). The sparse cells in the Foxn1 933/933 line were mainly CD45 -, revealing a severe lack of immature DN thymocytes. We assessed the effect on positive selection by screening for the upregulation of CD69 on cells expressing intermediate levels of TCRβ ( Figure  3C ). The percentage of CD69 + thymocytes expressing intermediate or high levels of the TCRβ subunit was reduced in the Foxn1 heterozygous mouse line (Foxn 933/1089 ) and in one of the homozygous mutant lines (Foxn1 1089/1089 ) ( Figure 3C ). These developmental abnormalities were of statistical significance, as revealed by comparisons of the different thymocyte subpopulations with multiple mice per group ( Figure 3D) . The consequence of the thymic aplasia (Foxn1 933/933 mice) and hypoplasia (Foxn1 1089/1089 and Foxn1 933/1089 lines) is an almost complete loss of mature CD4 + and CD8 + SP T cells in the peripheral lymph nodes of these mice ( Figure 4A) . B cells and NK cells were present, confirming the T -B + NK + SCID phenotype of Pt. 1 (Figure   4 , B-D). Comparison of the cell populations using 3-26 mice per group confirmed the statistical significance of the findings (Figure 4D) . The various cell populations in 6-week-old heterozygous mice (Foxn1 WT/933 and Foxn1 WT/1089 ) were similar to normal control cell populations, revealing that 1 functional allele of Foxn1 was sufficient to support normal T cell development (Supplemental Figure 2 , B-E). Taken together, our data demonstrate that T cell development is severely compromised in mice with compound heterozygous mutations in Foxn1 matching Pt. 1 and results in severe T cell lymphopenia. and mTECs (cytokeratin 5) revealed an almost complete absence of these cells in Foxn1 933/933 and Foxn 933/1089 mice relative to what we observed in the littermate controls ( Figure 5B ). Thymi from the Foxn1 1089/1089 line were not as severely affected, as small clusters of cTECs and mTECs were evident in the hypoplastic tissue. The number and percentage of cTECs and mTECs in these mice relative to littermate controls were determined by flow cytometry (Figure 5C) . With regard to cell percentages, the Foxn1 WT/WT mice had
Cortical and medullary TECs are affected by mutations in Foxn1. In the thymus, Foxn1 expression is restricted to ECs. To determine how the diverse Foxn1 mutations impact TECs, we compared cTEC and mTEC subsets. H&E staining of the tissue in the Foxn1 933/933 and Foxn 933/1089 lines revealed hypoplastic/aplastic tissue with poorly defined cortical and medullary segments, cystic regions, and increased adipose tissue ( Figure 5A ). Immunofluorescent staining with antibodies specific for cTECs (cytokeratin 8) ing, several additional FOXN1 mutations were identified in unrelated patients presenting with low T cell counts for whom exome sequencing was undertaken ( Table 2 ). Consistent with the location and type of mutation, either full-length or truncated Foxn1 proteins were expressed (Supplemental Figure 3, A and B) . The functional activity of Foxn1 mutations corresponding to those in Pt. 1 and Pt. 2, along with the additional mutations, were compared by transcriptional reporter assays using the promoter sequence for the Psmb11 gene, which encodes β5t (2). We found that Foxn1 933 had virtually no transcriptional activity (Figure 6C) . The Foxn1 constructs with mutations at positions 1089 and 1465 had 31% and 18% WT activity, respectively ( Figure 6D) . Interestingly, coexpression of the corresponding heterozygous mutation (Foxn1 1089 with Foxn1 933 ) or the polymorphism (Foxn1 1288 with Foxn1 1465 ) did not attenuate the transcriptional activity of the functional allele, suggesting that Foxn1 functions as a monomer ( Figure 6, C and D) . Foxn1 958 was inactive, whereas Foxn1 724 and Foxn1 962 had activity comparable to that of Foxn1 WT , at 95% and 82% normal values, respectively ( Table 2 and Supplemental Figure  3C ). Foxn1 982 and Foxn1 1075 exhibited 16% and 63% control activity, respectively ( Table 2 and Supplemental Figure 3C ). The deletions at positions 1201, 1293, and 1418 had a more severe effect, approximately 13% and 81% cTECs and mTECs (EpCam + CD45 -), respectively ( Figure 5, C and F) . In contrast, the Foxn1 1089/1089 thymi had 4% and 31% cTEC and mTEC representation, respectively ( Figure 5F ). The lower percentages in the Foxn1 1089/1089 mice were matched with an increased percentage of EpCam + CD45 -TECs from the Foxn1 1089/1089 mouse line (62%), which lacked the cytokeratin markers that distinguish cTECs and mTECs ( Figure 5C ). In normal mice, the mTECs were divided into the less mature MHC class II lo (MHC CII lo ) and more mature MHC class II hi (MHC CII hi ) cells ( Figure 5 , D and E). We detected a significant reduction in the percentage of MHC CII hi cells in the Foxn1 1089/1089 lines, and the MHC CII + cells present had a reduced cell-surface expression of this molecule relative to littermate controls ( Figure 5 , D and E). These TEC comparisons indicate that the mutations at the 1089 position of FOXN1 are not as damaging as those that disrupt the DNA-binding domain (position 933), providing some functionality for TEC development.
The transcriptional activity of Foxn1 is regulated by both the DNA-binding and transactivation domains. To determine how the distinct FOXN1 mutations identified in Pt. 1 and Pt. 2 affect the expression and function of the protein, we introduced substitutions or deletions into the cDNA of murine Foxn1 and performed protein expression and promoter-based reporter assay comparisons (2, 39) . The insertion of the 4-nt sequence identified in Pt. 1 (Foxn1 933 ) resulted in the expression of a truncated 50-kDa protein ( Figure  6A ). The 15-nt deletion, corresponding to the one identified in the second allele of Pt. 1 (Foxn1 1089 ), was almost identical in molecular mass to that of the WT control ( Figure 6A ). Foxn1 1288 was also similar in size to Foxn1 WT , whereas a single nucleotide deletion at position 1465 created a truncated protein with a mass of 65 kDa as a result of the frameshift ( Figure 6B ). As our studies were progress- Figure 6 . Functional impairment of Foxn1 is dependent on the location and type of mutation. (A-C) Transient transfection assays in HEK293T cells were performed with expression vectors for WT Foxn1 or Foxn1 constructs harboring the indicated mutations that matched the FOXN1 mutations identified in patients. The mutations were divided into those identified in Pt. 1 (A) (Foxn1 933 , Foxn1 1089 ) and Pt. 2 (B) (Foxn1 1288 , Foxn1 1465 ) as well as the indicated controls. Forty-eight hours after transfection, the cells were lysed, and the proteins were extracted and resolved by SDS-PAGE. Western blotting was performed with antibodies against Foxn1, followed by antibodies detecting GAPDH, which was used as a loading control. Blots are representative of 4 independent experiments. (C and D) HEK293T cells were transfected with the indicated constructs along with a Psmb11 luciferase reporter construct and a β-gal vector. The mutations (mFoxn1) were grouped for those identified in Pt. 1 (C) (Foxn1 933 , Foxn1 1089 ) and Pt. 2 (D) (Foxn1 1288 , Foxn1 1465 ) along with controls (D). Forty-eight hours after transfection, the cells were harvested, and luciferase activity was measured. The luciferase activity was normalized to β-gal, which was used as an internal control. Data are representative of triplicate samples from each group using 3 independent transfections per group. P values were determined using a standard 1-way ANOVA. jci.org Volume 129
Number 11 November 2019
identical to that of the classic nu/nu mouse, consistent with an essential role for the FOXN1 DNA-binding domain in both TEC and keratinocyte differentiation and gene expression. Contrasting with this, the Foxn1 933/1089 -knockin mouse line, genocopying Pt. 1, had a normal hair coat and whiskers despite the dramatic thymic hypoplasia. This suggests that the Foxn1 933/1089 mutations transcriptionally affect TECs differently than they do keratinocytes. We considered 2 explanations for the divergent consequences of harboring Foxn1 933/933 versus Foxn1 933/1089 genotypes for hair and nail reducing the functional activities of Foxn1 to 3%, 2%, and 12% of normal values, respectively ( Table 2 and Supplemental Figure  3D ). Taken together, these results confirm crucial roles for both the DNA-binding and transactivation domains in the transcriptional activity of Foxn1, with the extent of functional incapacitation being dependent on the location and type of Foxn1 mutation ( Figure 1C and Table 2) . FOXN1 differentially regulates genes in the thymus versus the skin. The Foxn1 933/933 homozygous knockin mice have a phenotype (D and E) qRT-PCR was performed to compare the levels of genes previously reported to be involved in hair shaft extension. This was performed to compare (D) 3 littermate controls and 3 Foxn1 933/933 mice and, in a separate experiment, (E) 3 controls and 3 Foxn1 933/1089 mice. The data shown reflect results from 1 of 2 independent experiments with 2 to 3 mice per group. # P = 0.02, ## P = 0.001, and #### P = 0.00006, by Student's t test. There were no significant differences in any of the transcripts compared between the 2 mouse lines in E. jci.org Volume 129 Number 11 November 2019 (2, 42) . This is best revealed in mouse models, in which enforced expression of Foxn1 in aged mice prevents the characteristic age-related thymic involution and improves T cell output (43) (44) (45) .
We identified what to our knowledge are several previously unreported mutations in human FOXN1 and, for 2 patients, distinct compound heterozygous mutations. Genocopying the compound heterozygous mutations identified in Pt. 1 using a mouse model was consistent with a novel clinical presentation of T -B + NK + SCID without evidence of alopecia or nail dystrophy. We identified the FOXN1 variants in Pt. 2 using targeted exome sequencing. However, this approach did not establish whether both variants were restricted to 1 allele, with the possibility that a normal FOXN1 sequence was present on the second allele. To answer this, we cloned the region comprising exon 8 and used more than 16 independently isolated bacterial clones to sequence the FOXN1 region comprising positions 1288 and 1465. Consistent with a compound heterozygous genotype, we confirmed individual allelic variants for positions 1288 and 1465. We also had an unexpected finding of some clones with a WT FOXN1 sequence. Although molecular analysis for maternal engraftment when the child was 2 months of age was negative, we suspect that the WT FOXN1 sequences were maternally derived, since DNA was obtained from the child's blood at 5 months of age (subsequent studies for maternal engraftment were not obtained at this time point). Moreover, the mother did not have any clinical indications of a T -/lo phenotype. The allelic variant at position 1288 did not affect the expression or function of full-length FOXN1, as established through Western blot analysis and a β5t luciferase reporter assay. The 1288 polymorphism is in fact reported in approximately 3% of the general population (dbSNP: rs61749867), suggesting that it is benign. However, the Pro-to-Ser amino acid change due to the 1288 polymorphism would result in a conformational modification in the protein.
This change could affect FOXN1 interactions with other proteins involved in thymopoiesis. Consequently, we cannot rule out the possibility that the 1288 variant has a functional impact in vivo in the context of a second allelic FOXN1 pathogenic variant. We are currently testing this in additional mouse models. Our characterization of the human FOXN1 mutations in mouse models has uncovered what we believe to be a novel region at the COOH-terminal end of the DNA-binding domain that uncouples TEC development from keratinocyte differentiation. Comparison of the thymic hypoplasia in the Foxn1 933/1089 and Foxn1 1089/1089 mouse lines revealed a critical 5-amino acid stretch in Foxn1 that was deleted as a result of the 1089 mutation in Pt. 1. This 5-amino acid segment is highly conserved with Foxn4, an ancestral gene present in all species that evolved with a thymus or thymus-like structure (thymoid) (Supplemental Figure 4) (16) . The thymus/thymoid-like structures are present in cartilaginous fish (sharks) and agnathans (lampreys), but not in cephalochordates (segmented marine animals such as lancelets) (19) . Interestingly, the 5-amino acid sequence in the lancelet Foxn4 diverges from that in lamprey, potentially explaining the emergence of the thymus-like structure (16) . Possible interactions between this 5-amino acid stretch and distinct transcription factors and/or other DNA-binding proteins could account for the differential function in TECs versus keratinocytes. Although one nuclear localization site (NLS) prediction program suggested that this site was an NLS, we noted that the phenotypes. First, the FOXN1 933/1089 mutations could selectively affect the TEC transcriptome as opposed to the keratinocyte transcriptome. Alternatively, the loss-of-function mutations in FOXN1 could modulate RNA transcripts in both TECs and keratinocytes in a quantitative manner, with the latter cell population maintaining reduced yet sufficient levels of transcripts to enable extrusion of the hair shaft and nail beds. To address these possibilities and characterize the transcript changes that resulted from the compound heterozygous mutations in FOXN1, we performed comparative gene expression analyses. RNA was extracted from embryonic thymic lobes at E13.5 and used for gene analyses. The E13.5 time point coincides with an expansion/differentiation phase of TECs prior to significant thymocyte expansion. We made gene expression comparisons with 3 control thymi (Foxn1 WT/WT ) and 3 hypoplastic thymi (Foxn1 933/1089 ) ( Figure 7A ). Gene array comparisons revealed 417 upregulated and 500 downregulated genes in the Foxn1 933/1089 line relative to the littermate controls ( Figure 7A ). These differences were not surprising, given the severe hypoplasia evident in the Foxn1 933/1089 mice ( Figure 3B ). Our focus on a select subset of transcripts with roles in the development of the thymus and parathyroids, which are linked during the patterning of the third pharyngeal apparatus, revealed some surprising differences ( Figure 7B ). Tbx1 and Eya1 levels were higher in mutant mice, suggesting impaired differentiation of the thymus within the third pharyngeal pouch region ( Figure 7B and Supplemental Table 3 ). In contrast to this, we found that Pax1 and Dcs2 levels were substantially lower in mutant mice (Supplemental Table 3 ). Although Pax1 participates in the formation of the thymic lobes, Dsc2 has only been described as a Foxn1 target in the skin (3, 40) . Taken together, our data are consistent with previous reports comparing normal and Foxn1-mutant mice and provide further insights into the transcript changes in embryonic hypoplastic thymi (2) .
To determine how the same mutations in Foxn1 affect hair follicle development, we isolated skin from 4-day-old pups. This is a stage when hair follicle extrusion and whisker formation is first evident in normal mice ( Figure 7C ). As previously reported, the Foxn1 933/933 pups showed no hair follicle extrusion ( Figure 7C ). In contrast, the hair in the Foxn1 933/1089 mice was visually similar to that of littermate controls ( Figure 7C ). We performed quantitative reverse transcription PCR (qRT-PCR) to compare a number of key genes expressed along the developing hair shaft needed for hair follicle extrusion. The nude mice (Foxn1 933/933 ) had reduced expression of mouse Krt84 (mKrt84), mKrt33, mKrt33b, and mDsc2, consistent with the central role of the DNA-binding activity of Foxn1 in enabling keratinocyte functions ( Figure 7D ). Foxn1 933/1089 mice have no nude phenotype. The transcripts coupled to hair follicle extrusion in these mice were expressed at levels comparable to those seen in littermate controls ( Figure 7E ). This indicates a functional dichotomy in the requirements for Foxn1 in controlling extrusion of the hair shaft in comparison with expression of thymus-selective genes.
Discussion
FOXN1 is a master transcriptional regulator of TECs that controls the expression of genes critical for both cTEC and mTEC differentiation and expansion (1, 28, 41 (51, 52) . In view of the likelihood that the 2 alleles of FOXN1 produce proteins that function independently, patients with single-allele mutations should be followed at least for several months to a year prior to considering thymus transplantation.
Methods
Antibodies, oligonucleotides, and plasmids. The antibodies used in the experiments as well as their sources and the plasmids used for transfections are listed in Supplemental Table 4 . Oligonucleotide sequences used for genotyping, PCR reactions, qRT-PCR reactions, and sequencing are listed in Supplemental Table 5 . The murine Foxn1 cDNA was cloned from genomic DNA using E14.5 fetal thymi isolated from C57BL/6 timed pregnant mice. The sequence was confirmed by Sanger sequencing after the RT-PCR product was subcloned into the pCR2.1-TOPO TA cloning vector (Thermo Fisher Scientific). The murine Foxn1 cDNA was subcloned into the pCMV-FLAG-vector (MilliporeSigma) using the Bgl II/Kpn I restriction enzyme cloning sites. Site-directed mutagenesis was performed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The human FOXN1 mutations were introduced into the murine equivalent location with complementary oligonucleotide primers, which are listed in Supplemental Table 5 . All mutated sequences were confirmed with DNA sequencing. Exon 8 from genomic DNA obtained from Pt. 2 was prepared and subcloned by PCR reactions using LA-Taq (Takara). The PCR reactions were resolved on agarose gels, and a 479bp fragment was isolated and subcloned into pCR2.1 using the TOPO-TA Cloning System (Thermo Fisher Scientific). Eighteen independent clones were expanded and used for sequencing with T7 primers. Thymocyte and EC preparations. Thymocyte and peripheral T cell populations were processed and stained for flow cytometric analyses as previously described (53, 54) . TECs were isolated from individual thymic lobes by digestion in Liberase (Roche) in the presence of DNase I (Roche) as described previously (55) . The cells were stained with antibodies against CD45 (Tonbo Scientific), MHC CII (I-A/I-E) (Tonbo Scientific), EpCAM (eBioscience), BP-1 (eBioscience), and UEA-1 (Vector Laboratories). Samples were analyzed on a FACSCanto II Flow Cytometer (BD Bioscience. FlowJo software (Tree Star) was used to analyze the flow data. TEC subsets were analyzed by selection of CD45 -EpCAM + MHCII + cells with either UEA1 + BP1for medullary TECs or BP1 + UEA1for cortical TECs. MHC CII hi and MHC CII lo cells were used to discriminate between the 2 cortical and 2 medullary TEC subsets. Thymocyte subsets and peripheral T cells were analyzed for cell-surface expression of various proteins including CD3, CD4, CD8, CD11b, CD11c, CD19, CD25, CD44, CD45, CD69, B220, NK1.1, αβ TCR, γδ TCR, and Ter119 (see Supplemental Table 4 for antibody sources).
RNA isolation and analysis. RNA was isolated from adult thymic tissues and P4 skin with miRNAeasy kits (QIAGEN). The tissues were Foxn1 1089 protein could translocate into the nucleus. Further supporting our suggestion that the nuclear localization remains intact with the 15-nt deletion in Foxn1 1089 is the observation that the compound heterozygous mice (Foxn1 933/1089 ) genocopying Pt. 1 had normal transcript levels of genes necessary for hair follicle extrusion. In most studies to date, Foxn1 appears to have overlapping requirements for both TEC and keratinocyte development (46) . To our knowledge, only 1 report has revealed a differential contribution of Foxn1 in TECs versus keratinocytes (18, 47) . In the published study, the removal of exon 3 selectively caused thymic aplasia, with no effects on hair shaft or nail bed development (47) . It remains unknown how the exon 3 deletion results in the differential effects of Foxn1 on TECs versus keratinocytes.
A second important region in Foxn1 is the transactivation domain, encoded within exons 8-9 (18) . The compound heterozygous mutations in Pt. 1 are proximal to this transactivation domain. In addition, Pt. 2 presented with a mutation at 1465, which affects the transactivation domain. The introduction of this 1465 deletion mutation in murine Foxn1 resulted in the expression of a truncated protein that had only 18% normal transcriptional activity, even though the DNA-binding domain remained intact. This confirms a critical role for the transactivation domain in TEC development, possibly via interactions with a yet-to-be identified coactivator. Alternatively, the mutations near the transactivation domain may provide additional DNA-binding specificity for induction of TEC-selective genes, and keratinocytes may not require this binding specificity.
Several additional patients were identified through SCID screening of newborns with low TREC numbers and were found to have mutations on just 1 allele of FOXN1. These mutations affected multiple regions in FOXN1, including the DNA-binding and/or transactivation domains ( Table 2 and Supplemental  Table 2 ). Although not predicted to be causal to a SCID phenotype because of the presence of 1 WT allele, such mutations could lead to reduced T cell output, either during stress at birth or through aging. In mouse models, hypomorphic mutations in murine Foxn1 result in thymic involution as the mice age, contributing to reduced T cell output (42, 45, 48, 49) . It remains to be seen whether patients with single-allele mutations in FOXN1 have an earlier onset of thymic involution at birth due to stress and later in life. Although our comparisons of 24-week-old Foxn1 heterozygous mice (Foxn1 933/WT ) failed to reveal evidence of premature thymic involution, the impact of stress on thymopoiesis still needs to be assessed in these mice (50) . Among the patients with single-allele mutations were 2 individuals with the same mutation as that in Pt. 2, at position 1465. Pt. 7 has a mutation in the DNA-binding region of FOXN1 and was clinically reported to have very low T cell numbers and normal hair and nail beds. Such findings suggest that additional polymorphisms and/or mutations in noncoding regions of FOXN1 (intron, promoter, enhancer elements) could contribute to the low T cell counts noted in those with only 1 affected allele. Alternatively, mutations in other genes coupled to FOXN1 functions may further compound the effects of the identified singleallele mutations, as exemplified with the reported DOCK8 and/or CHD7 mutations in 2 of the patients ( Table 2 ).
In summary, we describe what we believe to be a new clinical presentation of a primary immunodeficiency related to comjci.org Volume 129 Number 11 November 2019
FOXN1 patients in the United States. Consent for sequencing of DNA from Pt. 2 was obtained. Sequence information on deidentified Pts. 3-16 were obtained under a protocol declared exempt by the IRB of the Duke University Health System. The data were forwarded by various clinicians throughout the United States. Animal experiments described in this work were approved by and conducted with oversight of the IACUC of UT Southwestern (APN nos. 2015-101247 and 2015-101163). Mice were housed in a specific pathogen-free facility at UT Southwestern Medical Center. The Foxn1-targeted mice were developed entirely on a C57BL/6 background. Although more than 40 founders were screened for each construct, 2 independent mouse lines were expanded for each of the mutations generated by CRISPR-Cas: the Foxn1 933 mutations (Foxn1-933 no. 17 and Foxn1-933 no. 30) and the Foxn1 1089 mutations (Foxn1-1089 no. B4 and Foxn1-1089 no. B15). The mice are described further in Supplemental Table 4 . The Foxn1 mouse lines were crossed for 1 to 2 generations with C57BL/6 mice prior to intercrossing.
